Kaveri leads CEPA's Global Health team. She has extensive experience of working with global health partnerships and donors on a range of strategic, analytical and review-based assignments. Her core expertise is in strategic reviews and evaluations for global health organisations and their programmes.
Kaveri Kumar is a principal consultant who leads CEPA's Global Health team. She has extensive experience of working with global health partnerships and donors on a range of strategic, analytical and review-based assignments. Her core expertise is in strategic reviews and evaluations for global health organisations and their programmes, having recently led a review of the Global Fund’s approach to investments in Resilient and Sustainable Systems for Health (RSSH), a review of Gavi’s market shaping policy, and several portfolio and grant-level mid and end term reviews for Unitaid on its investments in HIV (funding to CHAI for pediatric HIV treatment, funding for HIV self testing (HIVST), operational review of the Medicines Patent Pool (MPP), funding on point of care molecular diagnostics), TB (introduction of GeneXpert), malaria (investments in severe malaria), and hepatitis. Other key experience includes a value for money assessment of the Stop TB Partnership, a meta review of 14 country HSS evaluations to bring out key findings and learnings in support of the design of Gavi’s new Health Systems and Immunisation Strengthening (HSIS) framework, support to the Assistant Director General of the WHO Family, Women’s and Children’s Health Cluster in carrying out a strategic review of the cluster’s priorities, areas of work and organisation, and advice to the PMNCH for a number of years, including in reviewing the RMNCH commodities supply chain. She has expertise in key health technical issues such as health financing and costing, health economics, cost effectiveness and value for money assessments, impact assessment, market dynamics, and has a good understanding of the global health aid architecture and the funding approaches of several institutions. She has developed a strong understanding of country health systems through in-country work in Ethiopia, Nigeria, Tanzania, Kenya, Uganda, Mali, Burkina Faso, Ghana, South Africa, India, Bangladesh, Nepal, Indonesia, and Uzbekistan.
Recent News & insights
CEPA modelling shows the economic and public health impact of voluntary licensing
Licences negotiated by the Medicines Patent Pool will save the international community an estimated USD 3.5bn and 170k lives by 2030. This is according to a new methodology for estimating the impact of licences that was validated via a peer-reviewed article published in The Lancet.
CEPA evaluates Unitaid’s investments in Hepatitis C
Unitaid has invested more than US$45 million since 2015 in support of improving access to care for hepatitis C. We are pleased to have provided them with a portfolio evaluation and end of grant evaluations.